Corrections

Cancer
Volume 192 - Issue 11

It’s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials

Authors:  James W Denham, Ron Bender and William E J Paradice

Med J Aust 2010; 192 (11): 655. || doi: 10.5694/j.1326-5377.2010.tb03668.x
Published online: 7 June 2010
Download PDF (57 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

Incorrect formula and number of trial subjects in Box: In “It’s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials” in the 5 April 2010 issue of the Journal (Med J Aust 2010; 192: 393-396), in the Box, there was an error in the total number of prostate cancers detected in the screening arm of the ERSPC trial and in the formula used to calculate differences between the two arms. The Box, with corrected figures in the last two columns and a replacement formula in a footnote, is reproduced here.

Staging and prostate cancer deaths among men participating in the PLCO and ERSPC trials5,6

Control arm

Screening arm

STAGE OF CANCER AT DIAGNOSIS

PLCO Trial

n = 2940

n = 3437

RD (%)*

Stage 1

15 (0.5%)

18 (0.5%)

+ 2.6%

Stage 2

2790 (94.9%)

3297 (95.9%)

+ 1.1%

Stage 3

56 (1.9%)

49 (1.4%)

– 25.2%

Stage 4

79 (2.7%)

73 (2.1%)

– 21.0%

ERSPC

n = 4611

n = 6169

RD (%)*

Stage T1a,b

277 (6.0%)

212 (3.4%)

– 42.8%

Stage T1c

1805 (39.1%)

3477 (56.4%)

+ 44.0%

Stage T2

1320 (28.6%)

1755 (28.4%)

– 0.6%

Stage T3

749 (16.2%)

509 (8.3%)

– 49.2%

Stage T4

156 (3.4%)

67 (1.1%)

– 67.9%

Stage M1

304 (6.6%)

149 (2.4%)

– 63.4%

CAUSE OF DEATH (in men diagnosed with prostate cancer)

PLCO Trial

Rate ratio†

Prostate cancer

82

92

1.11

Other causes‡

225

312

—

ERSPC

Prostate cancer

326

214

0.80

Other causes

ns

ns

ns

ERSPC = European Randomized Study of Screening for Prostate Cancer. ns = not specified. PLCO = Prostate, Lung, Colon and Ovarian. RD = relative difference.
* The relative difference is the percentage increase or decrease in cases of a given stage of prostate cancer detected by screening, using the formula RD = {[(proportion in screened arm ÷ proportion in control arm) × 100] – 100}%. eg, for the PLCO Trial, Stage 3, RD = {[(49/3437 ÷ 56/2940) × 100] – 100}% = –25.2%. † Rate ratio = adjusted value given by the authors.5,6 ‡ Men with prostate cancer dying of other causes.

Authors

  • James W Denham
  • Ron Bender
  • William E J Paradice
View this article on Wiley Online Library